|
Pre-congress briefing 23 October 2007
|
| THE IMPORTANCE OF KNOWLEDGE SHARING IN THE CNS SECTOR |
|
| 08.00 | Registration and coffee
|
| |
|
| 09.00 | Chairman’s opening remarks
|
| | Lars Sundstrom, Founder and Chief Scientific Officer, Capsant Neurotechnologies Ltd.
|
| 09.15 | Keynote address: knowledge sharing in CNS: sampling and visualising chemical-biological space
- Approaches to analysing high throughput screening data
- Data reduction to a humanely interpretable form
- Utilising video walls and data visualisation tools
|
| | Trevor Howe, Head of Molecular Informatics, Johnson & Johnson Pharmaceutical Research and Development
|
| CNS BIOMARKER DEVELOPMENT: IDENTIFYING DISEASE-RELATED MOLECULES LINKED TO NEUROLOGICAL DISEASE |
|
| 09.45 | Keynote address: biomarkers for CNS disease: from genetics to therapeutics
-
Metabolic impairments in schizophrenia
-
Receptor-based biomarkers for treating schizophrenia
-
Imaging biomarkers in Alzheimer’s disease
-
Genetics: a starting point for the next generation of CNS biomarkers?
-
The Biomarkers Consortium: neuroscience |
| | Antony Altar, Director of the Biomarkers Consortium, Foundation for the NIH
|
| 10.15 | Preliminary results of a novel diagnostic test as a key biomarker for CNS disorders
-
The increasing importance of personalised medicine
-
Targeting a drug treatment to a specific disease sub-population
-
Differentiating patients based on blood samples |
| |
|
| 10.45 | Morning coffee
|
| |
|
| 11.30 | The role of FMRI in drug discovery
|
| | Richard Wise, fMRI Director, Cardiff University Brain and Repair Imaging Centre
|
| 12.00 | Panel session: what makes the most effective biomarkers and what alternative methods are available?
|
| | Moderator: Antony Altar, Director of the Biomarkers Consortium, Foundation for the NIH Confirmed: Richard Wise, fMRI Director, Cardiff University Brain and Repair Imaging Centre
|
| 12.45 | Lunch
|
| |
|
| TAKING DRUGS FROM DISCOVERY TO DEVELOPMENT |
|
| 14.15 | Integrating biomarkers into the development of disease-modifying therapies for Alzheimer’s disease
-
Role of biomarkers and diagnostic imaging in Alzheimer's disease
-
First generation amyoid aggregation inhibitors currently in clinical trials
-
Lead optimisation of more potent compounds in development |
| |
|
| 14.45 | Receptor interaction possibilities for treatment of CNS disorders
-
Receptor interactions based on long lasting effects and receptor kinetics
-
Possibilities to improve effect duration
-
Neurpepetide receptor interactions and the possibilities for CNS disease treatment
-
The role of different receptor families, such as the adrenergic receptor family (Family A) and the secretin receptor family (family B). |
| | Bengt von Mentzer, Principal Scientist, Molecular Pharmacology Discovery, AstraZeneca
|
| 15.15 | Afternoon tea
|
| |
|
| 16.00 | Application of 3D in-vitro platforms for lead optimisation studies
-
Bridging the gap between discovery and animal models
-
Applications of 3D in-vitro systems to CNS drug safety and efficacy studies
-
Novel stem cell platforms for lead optimisation studies |
| | Lars Sundstrom, Founder and Chief Scientific Officer, Capsant Neurotechnologies Ltd.
|
| 16.30 | Addressing continuing unmet needs with improved symptomatic therapies for neurological diseases
-
The role of symptomatic therapies in the area of disease-modification
-
BTG’s neuroscience pipeline
-
Case studies – BGC20-1259 – a multifunctional drug for Alzheimer’s disease and late-life depression
|
| | Russell Hagan, Head of Research and Development, BTG International Ltd
|
| 17.00 | Chairman’s closing remarks
|
| |
|
|
Conference day one 24 October 2007
|
| KEY ADVANCES IN THERAPEUTICS FOR NEURODEGENERATIVE DISORDERS AND BEYOND |
|
| 08.00 | Registration and coffee
|
| |
|
| 08.45 | Chairman’s opening remarks
|
| | Eric Parker, Senior Director, Department of Neurobiology, Schering-Plough Research Institute
|
| 09.00 | Keynote address: neural stem cells as drug targets for neurodegenerative diseases
-
Advancement in the understanding of neurogenesis
-
Regulation of neural stem cells
-
Preclinical models for neurogenesis drug discovery |
| | Aaron Chuang, Drug Discovery Stem Cell Coordinator and Manager of Cellular Neurobiology, Neurodegeneration Research Department, Glaxosmithkline
|
| 09.30 | Activating the endogenous stem cells with drugs: a novel approach in clinical trials
-
The potential of stem cell therapies
-
Targeting Parkinson's disease, stroke, cognition / mood disorders and orphan CNS indications
-
Stem cell based therapies now entering into clinical trials |
| |
|
| 10.00 | CNS disorders as post traumatic stress diseases (PTSD)
-
High cortisol major cause of CNS disorders
-
High cortisol as spoiler of stem cell therapy
-
Our approach to CNS diseases – amniotic epithelial cells (AEC) plus cortisol modulators. |
| |
|
| 10.30 | Morning coffee
|
| |
|
| 11.15 | Developing a stem cell therapy for Parkinson's disease
-
Using ReNeuron’s c-mycER proprietary technology to develop a scalable and stable dopaminergic neuronal stem cell line
-
Developing new technologies for dopamine neuron delivery to the brain
-
Achieving proof of concept |
| | John Sinden, Founder and Chief Scientific Officer, ReNeuron
|
| 11.45 | Panel session: key successes in stem cell therapies and where do we go from here?
-
What is the real potential of stem cell therapies?
-
A review of results in clinical trials
-
Which therapeutic areas show the most potential for success? |
| | Confirmed: John Sinden, Founder and Chief Scientific Officer, ReNeuron Confirmed: Aaron Chuang, Drug Discovery Stem Cell Coordinator and Manager of Cellular Neurobiology, Neurodegeneration Research Department, Glaxosmithkline
|
| 12.30 | Speed networking
|
| |
|
| 13.15 | Lunch
|
| |
|
| 14.45 | Increasing dopamine synthesis in Parkinson’s disease via gene therapy
-
A novel gene-based therapeutic for the treatment of Parkinson’s disease
-
Using a vector to carry genes encoding the enzymes needed for dopamine synthesis
-
Preclinical efficacy data in an in vivo model of Parkinson’s disease
-
Preparation for a Phase I/II human trial patients with moderate to late-stage Parkinson’s disease |
| |
|
| 15.15 | Gene therapy for neurodegenerative diseases: an AAV genetic delivery mechanism
-
Nonpathogenic adeno-associated virus genetic delivery mechanism
-
Therapeutic gene unique to each indication
-
Applications in Parkinson’s disease and epilepsy |
| | John Mordock, President and Chief Executive Officer, Neurologix, Inc.
|
| 15.45 | Attacking beta amyloid accumulation: Alzheimer’s antibodies
-
Background: Beta-amyloid hypothesis of Alzheimer's disease (AD)
-
Active versus passive immunization approaches
-
Studies in transgeneic mouse models of AD
-
Clinical trials of anti-Ab immunotherapies in AD patients
-
Outlook: Future directions in AD immunotherapy |
| | Klaus Mendla, Head of CNS Therapeutic Advisory Team, Department of Research and Development Licensing and Information Management, Boehringer Ingelheim
|
| SMALL MOLECULE DRUGS BEING DEVELOPED TO TREAT NEURODEGENERATIVE DISEASE |
|
| 16.45 | 16.45 Secretase inhibitors for the treatment of alzheimer's disease: the cutting edge or cutting it too close?
-
Therapeutic potential: reduction of Ab peptides by BACE and g-secretase inhibitors
-
Identification and mitigation of the side effects of g-secretase inhibitors
-
Recent insights into the efficacy and side effect potental of BACE inhibitors |
| | Eric Parker, Senior Director, Department of Neurobiology, Schering-Plough Research Institute
|
| 16.45 | Afternoon tea
|
| |
|
| 17.15 | Recent progress and major challenges in the search for disease modifying therapies for Parkinson’s disease
-
Mechanisms of cell death
-
Neurotoxin models and their use (MPTP, 6-OHDA)
-
Pharmacological approaches for neuroprotection and neurorescue
-
Newer animal models (proteosome pathway and transgenic model)
-
New leads from the study of genetic factors |
| |
|
| 17.45 | Neuroprotective targets in excitotoxicity – the postsynaptic density and beyond
-
Excitotoxic neuronal death contributes to many neurological disorders
-
Rho as a novel and essential component of the excitotoxic cell death pathway
-
Protein-protein interactions specifically involved in neurotoxic signaling
-
The design and validation of short neuroprotective peptides |
| | Michael Courtney, Group Leader, Molecular Signalling Laboratory, Department of Neurobiology, University of Kuopio
|
| 18.15 | Chairman’s closing remarks
|
| |
|
| 18.25 | Networking drinks reception
|
| |
|
|
Conference day two 25 October 2007
|
| FUTURE OUTLOOK FOR DRUG DEVELOPMENT FOR PSYCHIATRIC DISORDERS |
|
| 08.00 | Registration and coffee
|
| |
|
| 08.45 | Chairman’s opening remarks
|
| |
|
| 09.00 | Keynote address: drug development for psychiatric disorders in the future: an overview of the challenges, strategies and approaches for the treatment of mood disorders
-
The current status of treatment for psychiatric conditions
-
Challenges and issues with current treatments
-
What should the future hold for drug development
-
Different approaches to drug discovery and development |
| | Lee Schechter, Therapeutic Area Head/Director, Depression and Anxiety Research, Neuroscience Discovery, Wyeth Research
|
| 09.30 | Future trends in anti-depression treatments
|
| | Nicholas Moore, Associate Director, Behavioural Pharmacology, Lundbeck Research USA Inc.
|
| 10.00 | Morning coffee
|
| |
|
| 10.45 | Clinical Progress of GABA Enhanced Anti-Psychotic for the Treatment of Schizophrenia
-
Pharmacology overview of a D2 antagonist GABA A agonists in animal models
-
Receptor occupancy (PET) results in healthy human volunteers
-
Phase IIa preliminary results in schizophrenic patients |
| | Yona Geffen, Senior Drug Development Manager, BioLineRx Ltd
|
| SMALL MOLECULE DRUG DISCOVERY |
|
| 11.15 | Drug discovery for psychiatric conditions: targeting the HPA axis
-
CRF1, V1b and GR antagonists
-
The therapeutic potential in depression and other stress-related disorders |
| | Thomas Steckler, Therapeutic Area Leader, Psychiatry & Biology Head, Johnson & Johnson
|
| 11.45 | Strategies for the development of antipsychotics: a review of recent approaches with a focus on third generation compounds combining activity at dopamine D2 and 5-HT1A receptors
-
Limited progress in schizophrenia management, and the dopamine (DA)
D2 receptor remaining as the target of choice
-
Several new approaches targeting other central systems 5-HT1A agonist activity to along with antagonism of DA D2 receptor as a promising strategy: focus on several compounds in various stages of development |
| | Ronan Depoortere, Head of Behavioral Pharmacology, Neurobiology 2 Division, Pierre Fabre
|
| 12.15 | Mechanism of action of dopamine system stabilisers
-
In vivo readouts to detect dopamine system stabilisers
-
In vitro effects on dopamine receptor signaling
-
Importance of intrinsic activity at dopamine receptors |
| | Shaun Jordan, Associate Director, Neuroscience Research, Otsuka Maryland Medicinal Labs, Inc.
|
| 12.45 | Lunch
|
| |
|
| 14.15 | Dopamine D3 receptor antagonism as a potential therapeutic target for treating schizophrenia
|
| |
|
| 14.45 | Enhancing NMDA receptor function in Schizophrenia
-
Deficient glutamatergic neurotransmission in schizophrenia
-
Modifying the function of the NMDA receptor
-
Developing Schizophrenia drugs which enhance NMDA receptor function |
| | John Kemp, Chief Executive Officer, Evotec Neurosciences
|
| 15.15 | Panel session: what are the most promising future therapies for the treatment of psychiatric disorders?
-
Novel therapeutic targets for drug development for psychiatric disorders
-
Breaking new boundaries: established vs. novel drugs and therapies
-
Treating the underlying cause rather than the effects |
| | Confirmed: Lee Schechter, Therapeutic Area Head/Director, Depression and Anxiety Research, Neuroscience Discovery, Wyeth Research Confirmed: Nicholas Moore, Associate Director, Behavioural Pharmacology, Lundbeck Research USA Inc. Confirmed: Thomas Steckler, Therapeutic Area Leader, Psychiatry & Biology Head, Johnson & Johnson Confirmed: Ronan Depoortere, Head of Behavioral Pharmacology, Neurobiology 2 Division, Pierre Fabre
|
| 16.00 | Afternoon tea
|
| |
|
| OVERCOMING THE GAPS IN NEUROLOGICAL DRUG DISCOVERY |
|
| 16.30 | SV2A selective drugs: a new approach for the treatment of epilepsy
-
All antiepileptic drugs (AEDs) reduce excitatory or enhance inhibitory neurotransmission
-
Synaptic vesicle protein 2A (SV2A) is involved in vesicle exocytosis and constitutes a novel target for AEDs
-
Involvement of this protein in the epileptogenic process and an implication in an epileptic condition |
| |
|
| 17.00 | Metabotropic glutamate receptors as targets for therapeutic interventions in CNS disorders
-
Pharmacological agents that act as selective agonists or antagonists and allosteric modulators for different metabotropic receptor subtypes
-
Their potential in the treatment of disorders such as anxiety, cognitive dysfunction, chronic pain and substance abuse
-
The functional and therapeutic effects of selective agents that act at these receptors |
| |
|
| 17.30 | A breakthrough in delivering compounds across the blood-brain barrier
-
The BBB as a major obstacle for CNS drug discovery
-
Temporarily and reversibly opening tight junctions at the BBB via oligoglycerolipids
-
Transporting non-BBB permeant molecule (atenelol) into the brain using the OGL-1 oligoglycerolipid |
| |
|
| 18.00 | Chairman’s closing remarks
|
| |
|
